Date: 2018-09-27
Type of information: Granting of the orphan status in the US
Product name: relacorilant (CORT125134)
Compound: relacorilant
Therapeutic area: Cancer - Oncology
Action mechanism: glucocorticoid receptor antagonist
Company: Corcept Therapeutics (USA - CA)
Disease: pancreatic cancer
Latest news:
Patents:
Submission of marketing authorization application USA :
Submission of marketing authorization application UE:
Withdrawal of marketing authorization application USA:
Withdrawal of marketing authorization application UE:
US authorization:
UE authorization:
Favourable opinion UE:
Favourable opinion USA:
Orphan status USA: 2018-09-27
Orphan status UE:
Pediatric exclusivit _USA:
Pediatric exclusivity UE: OTC status: Other news: